84.68
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $84.68, with a volume of 4.47M.
It is up +0.26% in the last 24 hours and up +6.53% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$84.53
Open:
$84.35
24h Volume:
4.47M
Relative Volume:
0.92
Market Cap:
$262.55B
Revenue:
$56.53B
Net Income/Loss:
$8.32B
P/E Ratio:
31.81
EPS:
2.6622
Net Cash Flow:
$8.49B
1W Performance:
-0.86%
1M Performance:
+6.53%
6M Performance:
+27.85%
1Y Performance:
+9.57%
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AZN
Astrazeneca PLC
|
84.66 | 262.09B | 56.53B | 8.32B | 8.49B | 2.6622 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
Feb-13-25 | Upgrade | UBS | Neutral → Buy |
Feb-12-25 | Initiated | Morgan Stanley | Overweight |
Nov-20-24 | Upgrade | UBS | Sell → Neutral |
Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
May-30-24 | Initiated | Goldman | Buy |
Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
Jan-23-24 | Initiated | Morgan Stanley | Overweight |
Jan-16-24 | Resumed | UBS | Sell |
Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jul-12-23 | Upgrade | UBS | Neutral → Buy |
Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-29-22 | Upgrade | Argus | Hold → Buy |
Jun-14-22 | Downgrade | UBS | Buy → Neutral |
Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
Aug-12-21 | Resumed | JP Morgan | Overweight |
Apr-12-21 | Downgrade | Argus | Buy → Hold |
Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
Feb-25-21 | Upgrade | UBS | Neutral → Buy |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-30-20 | Upgrade | UBS | Sell → Neutral |
Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
Sep-29-20 | Initiated | Berenberg | Buy |
Nov-22-19 | Initiated | SVB Leerink | Outperform |
Oct-25-19 | Upgrade | Liberum | Hold → Buy |
Apr-02-19 | Downgrade | UBS | Neutral → Sell |
Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
Dec-11-18 | Resumed | Jefferies | Hold |
Oct-09-18 | Initiated | Guggenheim | Buy |
Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
Feb-05-18 | Reiterated | Bernstein | Outperform |
Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Global markets live: Blackstone, Pfizer, Tesla, Stellantis, AstraZeneca… - MarketScreener
Will AstraZeneca PLC Depositary Receipt bounce back from current supportJuly 2025 Earnings & Real-Time Sentiment Analysis - newser.com
Will breakout in AstraZeneca PLC Depositary Receipt lead to full recoveryJuly 2025 Big Picture & Reliable Entry Point Trade Alerts - newser.com
Advanced analytics toolkit walkthrough for AstraZeneca PLC Depositary ReceiptJuly 2025 Pullbacks & Low Drawdown Investment Strategies - newser.com
AstraZeneca (AZN) Agrees to Lower Drug Prices in the U.S. with S - GuruFocus
AstraZeneca's drug pricing deal with Trump far from clear result, say analysts - Proactive financial news
Why AstraZeneca PLC Depositary Receipt stock remains undervaluedJuly 2025 Breakouts & Daily Technical Stock Forecast Reports - newser.com
AstraZeneca: Drug Pricing Agreement Mitigates Threats of Tariffs and Price Controls - Morningstar Canada
Vanguard Personalized Indexing Management LLC Increases Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Is AstraZeneca PLC Depositary Receipt stock ready for a breakoutWeekly Risk Summary & Weekly High Potential Stock Alerts - newser.com
Trending tickers: TSMC, AstraZeneca, Lloyds, Fresnillo and Canal+ - Yahoo
AstraZeneca confirms deal with US government on drug prices - MarketScreener
How to monitor AstraZeneca PLC Depositary Receipt with trend dashboardsMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com
AstraZeneca reaches agreement with Trump to lower its prices in the US - MarketScreener
AstraZeneca agrees to offer US discounts in exchange for no tariffs - Proactive Investors
AstraZeneca to cut US drug prices in key White House deal - Sharecast.com
AstraZeneca : Agreement with US Govt to lower medicine prices - MarketScreener
Trump announces deal with AstraZeneca on drug prices, tariffs - MarketScreener
AstraZeneca Plc Reaches Agreement With Trump Administration To Cut US Drug Prices - DirectorsTalk Interviews
AstraZeneca Joins US President Trump's Drug-Cost Initiative, Secures Tariff Reprieve - MarketScreener
US FDA Commissioner’s Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions - insights.citeline.com
President Trump announces deal with AstraZeneca on drug prices and tariffs - Taipei Times
Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump - MarketScreener
AstraZeneca PLC $AZN Shares Bought by Aberdeen Group plc - MarketBeat
AstraZeneca PLC $AZN Stock Holdings Lowered by US Bancorp DE - MarketBeat
AstraZeneca Signs US Drug Pricing Deal, Secures Three-year Delay to Tariffs - MarketScreener
Target Identification and Validation In Drug Discovery - Oncodaily
AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts - ts2.tech
Benson Investment Management Company Inc. Takes $4.44 Million Position in AstraZeneca PLC $AZN - MarketBeat
Mengis Capital Management Inc. Grows Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Acquired by Ramirez Asset Management Inc. - MarketBeat
AstraZeneca PLC $AZN Stock Holdings Lowered by Blair William & Co. IL - MarketBeat
Callan Family Office LLC Has $3.90 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Trump announces deal with AstraZeneca to cut drug prices across US - Hindustan Times
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
AstraZeneca Strikes 'Most Favored Nation' Price Deal - Law360
AstraZeneca (AZN) Reaches Agreement with White House to Lower Dr - GuruFocus
AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal - MarketScreener
AstraZeneca Agrees To Lower Drug Prices For Medicaid Under Trump Administration Deal - Barchart.com
AstraZeneca CEO says company granted three-year tariff exemption - MarketScreener
AstraZeneca : announces historic agreement with US Government to lower the cost of medicines for American patients - MarketScreener
Trump Announces AstraZeneca Drug Price Cuts for Tariff Reprieve - Yahoo Finance
Trump says AstraZeneca to offer drugs to US at discounted prices - Reuters
AstraZeneca (AZN) to Slash Drug Prices in New Deal - GuruFocus
Trump strikes drug-pricing deal with AstraZenecaMSNBC - MarketScreener
AstraZeneca’s stock is climbing after hours following a deal with the Trump White House - MarketWatch
AstraZeneca set to announce drug price deal with Trump administrationBloomberg By Investing.com - Investing.com South Africa
AstraZeneca follows Pfizer lead in making drug price deal with Trump - Seeking Alpha
Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income AmericansAstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca to strike landmark drug price deal with Trump administration - Business Standard
Market Voices: Trump slams China on rare earths, AstraZeneca, UPS - Seeking Alpha
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):